Esophageal Cancer Clinical Trials & Research

Researchers at Memorial Sloan Kettering are studying new approaches to esophageal cancer, and we come closer to finding exciting solutions every day. One of the most important goals we have is to develop better treatments for people with esophageal cancer who are not helped by standard treatments.

We lead clinical trials to make current treatments better and to enhance the quality of life for people with esophageal cancer. Eligible patients may get experimental treatments before they are widely available elsewhere.

Memorial Sloan Kettering’s clinical trials for esophageal cancer are listed below. There may be other trials that are right for your cancer. Consult with your physician, who can ask if a trial is right for you.

and/or
23 Clinical Trials found
A Phase 1 Study of ANS03 in People With Advanced Solid Tumors
This study includes people with these cancers:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of ASP2138 in People With Pancreatic Cancer or Stomach or Gastroesophageal Junction Cancer That Makes Claudin (CLDN) 18.2
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of BMS-986500 in People With Advanced Solid Tumors
Researchers are seeking the best dose of BMS-986500 to give alone and with other drugs in people with solid tumors. The people in this study have ovarian, endometrial, gastroesophageal, or breast cancer. Their tumors have spread beyond their original locations.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of FT825 CAR T-Cell Therapy With or Without Cetuximab in People With Solid Tumors
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth. 
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of Mesothelin-Targeted CAR T Cell Therapy in People With Esophagogastric Cancer
Researchers want to find the best dose of a new CAR T cell therapy for esophagogastric cancer. Esophagogastric cancer is cancer of the esophagus or stomach. The people in this study have esophagogastric cancer that has metastasized (spread), including to the peritoneum (lining of the belly). In addition, their cancer makes a protein called mesothelin and keeps growing after initial treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of Valemetostat Tosylate in Combination With Dato-DXd in People With Lung Cancer and With T-DXd in People With Digestive Cancers
Researchers are finding the best doses of valemetostat tosylate and datopotamab deruxtecan (Dato-DXd) to use in people with lung cancer. In a second part of the study, researchers are finding the best doses of valemetostat tosylate and trastuzumab deruxtecan (T-DXd) to use in people with digestive cancers.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2a Study of EVM14 Alone or With Pembrolizumab Immunotherapy in People With Advanced Solid Tumors
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of FOG-001 in People With Advanced Cancer
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer
Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau